IL2 and neoplasm: These include direct cytotoxicity against tumor cells [71]; promotion of T cell and natural killer cell proliferation and activation [72]; enhancement of antitumor immune responses by increasing the production of cytokines such as interleukin-2 (IL-2) and interferon-gamma (IFN-γ) [73]; suppression of Treg function [74]; inhibition of angiogenic factors such as vascular endothelial growth factor (VEGF), thereby preventing tumor growth and metastasis [75]; and binding to cereblon, leading to the degradation of lymphoid transcription factors IKZF1 and IKZF3 [76,77].